Lataa...
Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
INTRODUCTION: Enzalutamide is an oral androgen receptor (AR) signaling inhibitor that was specifically engineered to overcome castration-resistant prostate cancer (CRPC) harboring AR amplification or overexpression. Enzalutamide has demonstrated significant activity in men with metastatic CRPC. AIMS...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3622394/ https://ncbi.nlm.nih.gov/pubmed/23589709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CE.S34747 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|